BioPharma Dive November 4, 2024
The collaboration will advance a once-monthly shot for obesity and diabetes as doctors struggle to keep patients on existing GLP-1 drugs.
Dive Brief:
- Novo Nordisk is investing further in obesity and metabolic disease, signing a deal to use Ascendis Pharma’s delivery technology to advance a long-acting GLP-1 drug as well as develop products in diabetes and cardiovascular conditions, Ascendis said Monday.
- Per deal terms, Novo could pay up to $285 million in immediate and milestone-based fees to Ascendis for the GLP-1 drug, depending on its progress toward approval. In addition, Ascendis could receive up to $77.5 million for each additional drug developed.
- Ascendis has won Food and Drug Administration approval of two products using its extended release technology, both...
Today's Sponsors
Today's Sponsor